Raffaele Colombo
@raffcolo
Followers
2K
Following
3K
Statuses
847
ADCs, targeted therapies, chemistry, biotech, pharma. Associate Director @ Zymeworks
Vancouver, British Columbia
Joined October 2022
🎉 It's an incredible honor and privilege to be named one of the 2024 PharmaVoice 100 by @PharmaVoice, alongside so many talented and inspiring leaders in the life sciences industry! 🎉 Check out the full list of this year #PharmaVoice100 honorees here:
1
0
15
@BertrandBio @BowTiedBiotech @JacobPlieth oh yes... their database is a good start, but preclinical assets are always confusing (= they capture the same one with multiple names, they look at those in publications/presentations that will never make into the clinic, etc...).
0
0
2
@BowTiedBiotech @JacobPlieth Not sure where those numbers came from... but for ADCs: B7H3 = 4 clinical programs up to end of 2021, now 16 (15 active, +1 discontinued) B7H4 = 1 clinical program up to end of 2021, now 6 (5 active, +1 just discontinued)
1
1
3
First ADC discontinued in 2025👇
$PFE confirmed to me that it HAS dropped its B7-H4 ADC felmetatug vedotin after all. Scoop via @ApexOnco
3
2
16
@JacobPlieth Yes, drug-linker is from DualityBio (DITAC) with P1021 Topo1i payload for their uPARAP. TF with Multitude T1000 exatecan.
1
0
3
RT @AACRFoundation: Can prevention and early detection significantly reduce the burden of cancer? The @AACR and its members have long focus…
0
2
0
@DrPaulyDeSantis @JacobPlieth We summarized all the topo payloads in the clinic with known structures last year in our MCT paper… the list is much longer a year later!
1
0
2
Now with two bangs!!
T-DXd is now approved for the 1L cytotoxic treatment of patients with HR+/HER2-low or #ultralow MBC, based on the results of DB06. Best suited in this 1L setting for pts with visceral and aggressive disease. Next step: unlocking the full spectrum of HER2.
0
0
4
RT @PTarantinoMD: Final analysis of the PRECIOUS phase 3 trial out in @JCO_ASCO. Despite yielding only a small PFS advantage, pertuzumab re…
0
35
0
For degraders aficionado... International Nonproprietary Names (INN) for bifunctional degraders still in discussion, but: - suffix will be "-deg" - reference to the POI as name infix - targets grouped where possible under a single infix (Current names will not be changed)
International Nonproprietary Names have meanings! RVMD requested to reference RAS(ON) in their names (-rasonib or -onrasib) to distinguish them from other KRASi 👇 WHO chose "-onrasib" For mAbs, the original "-mab" stem is now superseded by 4 new ones: -tug, -bart, -ment, -mig
0
0
6
In addition, several trial in progress posters, including: - sacituzumab tirumotecan (sac-TMT) - trastuzumab deruxtecan (T-DXd) - patritumab deruxtecan (MK-1022, HER3-DXd) - GSK5764227 (HS-20093) - ADCT-701 Full abstracts:
0
0
0
